Protein engineering strategies for the development of viral vaccines and immunotherapeutics

Jayne F. Koellhoffer; Chelsea D. Higgins; Jonathan R. Lai

doi:10.1016/j.febslet.2013.10.014

Protein engineering strategies for the development of viral vaccines and immunotherapeutics

Jayne F. Koellhoffer, Chelsea D. Higgins, Jonathan R. Lai

Biochemistry

Research output: Contribution to journal › Review article › peer-review

17 Scopus citations

Abstract

Vaccines that elicit a protective broadly neutralizing antibody (bNAb) response and monoclonal antibody therapies are critical for the treatment and prevention of viral infections. However, isolation of protective neutralizing antibodies has been challenging for some viruses, notably those with high antigenic diversity or those that do not elicit a bNAb response in the course of natural infection. Here, we discuss recent work that employs protein engineering strategies to design immunogens that elicit bNAbs or engineer novel bNAbs. We highlight the use of rational, computational, and combinatorial strategies and assess the potential of these approaches for the development of new vaccines and immunotherapeutics.

Original language	English (US)
Pages (from-to)	298-307
Number of pages	10
Journal	FEBS Letters
Volume	588
Issue number	2
DOIs	https://doi.org/10.1016/j.febslet.2013.10.014
State	Published - Jan 21 2014

Keywords

Antibody engineering
Antiviral immunotherapy
Immunogen design

ASJC Scopus subject areas

Biophysics
Structural Biology
Biochemistry
Molecular Biology
Genetics
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.febslet.2013.10.014

Cite this

@article{7a5954c18ea147cd9ad3cc0932ad2840,

title = "Protein engineering strategies for the development of viral vaccines and immunotherapeutics",

abstract = "Vaccines that elicit a protective broadly neutralizing antibody (bNAb) response and monoclonal antibody therapies are critical for the treatment and prevention of viral infections. However, isolation of protective neutralizing antibodies has been challenging for some viruses, notably those with high antigenic diversity or those that do not elicit a bNAb response in the course of natural infection. Here, we discuss recent work that employs protein engineering strategies to design immunogens that elicit bNAbs or engineer novel bNAbs. We highlight the use of rational, computational, and combinatorial strategies and assess the potential of these approaches for the development of new vaccines and immunotherapeutics.",

keywords = "Antibody engineering, Antiviral immunotherapy, Immunogen design",

author = "Koellhoffer, {Jayne F.} and Higgins, {Chelsea D.} and Lai, {Jonathan R.}",

note = "Funding Information: J.R.L. acknowledges funding from the National Institutes of Health (R01-AI090249). J.F.K. was supported in part by NIH Medical Scientist Training Grant T32-GM007288.",

year = "2014",

month = jan,

day = "21",

doi = "10.1016/j.febslet.2013.10.014",

language = "English (US)",

volume = "588",

pages = "298--307",

journal = "FEBS Letters",

issn = "0014-5793",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Protein engineering strategies for the development of viral vaccines and immunotherapeutics

AU - Koellhoffer, Jayne F.

AU - Higgins, Chelsea D.

AU - Lai, Jonathan R.

N1 - Funding Information: J.R.L. acknowledges funding from the National Institutes of Health (R01-AI090249). J.F.K. was supported in part by NIH Medical Scientist Training Grant T32-GM007288.

PY - 2014/1/21

Y1 - 2014/1/21

N2 - Vaccines that elicit a protective broadly neutralizing antibody (bNAb) response and monoclonal antibody therapies are critical for the treatment and prevention of viral infections. However, isolation of protective neutralizing antibodies has been challenging for some viruses, notably those with high antigenic diversity or those that do not elicit a bNAb response in the course of natural infection. Here, we discuss recent work that employs protein engineering strategies to design immunogens that elicit bNAbs or engineer novel bNAbs. We highlight the use of rational, computational, and combinatorial strategies and assess the potential of these approaches for the development of new vaccines and immunotherapeutics.

AB - Vaccines that elicit a protective broadly neutralizing antibody (bNAb) response and monoclonal antibody therapies are critical for the treatment and prevention of viral infections. However, isolation of protective neutralizing antibodies has been challenging for some viruses, notably those with high antigenic diversity or those that do not elicit a bNAb response in the course of natural infection. Here, we discuss recent work that employs protein engineering strategies to design immunogens that elicit bNAbs or engineer novel bNAbs. We highlight the use of rational, computational, and combinatorial strategies and assess the potential of these approaches for the development of new vaccines and immunotherapeutics.

KW - Antibody engineering

KW - Antiviral immunotherapy

KW - Immunogen design

UR - http://www.scopus.com/inward/record.url?scp=84892373125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892373125&partnerID=8YFLogxK

U2 - 10.1016/j.febslet.2013.10.014

DO - 10.1016/j.febslet.2013.10.014

M3 - Review article

C2 - 24157357

AN - SCOPUS:84892373125

SN - 0014-5793

VL - 588

SP - 298

EP - 307

JO - FEBS Letters

JF - FEBS Letters

IS - 2

ER -

Protein engineering strategies for the development of viral vaccines and immunotherapeutics

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this